Jenny Zhang

Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer.

J. Ajani, T. Zander, A. Lièvre, 2021, The New England journal of medicine.

Maintenance therapy with avelumab (MSB0010718C; anti-PD-L1) vs continuation of first-line chemotherapy in patients with unresectable, locally advanced or metastatic gastric cancer: The phase 3 JAVELIN Gastric 100 trial.

J. Taieb, N. Boku, J. Gurtler, 2016 .

Avelumab (MSB0010718C; anti-PD-L1) + best supportive care (BSC) vs BSC ± chemotherapy as third-line treatment for patients with unresectable, recurrent, or metastatic gastric cancer: The phase 3 JAVELIN Gastric 300 trial.

Y. Bang, F. Ciardiello, L. Wyrwicz, 2016 .

Adjuvant nivolumab (NIVO) in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiotherapy (CRT): Expanded efficacy and safety analyses from CheckMate 577.

J. Ajani, T. Zander, A. Lièvre, 2021 .